Use of Ketamine as an Anesthetic, Antidepressant, and Treatment for Irritability Associated with ASD
Article Sidebar
Main Article Content
Abstract
This essay explores how ketamine operates as an anesthetic and as an antidepressant through separate but linked mechanisms. Drug repurposing is the application of a drug for a new medical use different from its original purpose, as indicated by the FDA. By comparison of peer-reviewed research on PubMed, NCBI, and clinical trials of ketamine's pharmacology, we find that the mechanism of its use in depression and irritability with Autism Spectrum Disorder (ASD) is derived from blocking the NMDA receptor. As an anesthetic, ketamine rapidly binds to the NMDA receptor and blocks signals that cause excitement and induces dissociation. As an antidepressant, ketamine slowly blocks NMDA receptors. This has the effect of creating the mTOR pathway, which causes synaptogenesis and neural regeneration. In either case, ketamine is beneficial, but must be watched as it has some side effects and is addictive. Future research is extremely vital in determining long-term side effects and realizing its full medical potential.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
E., Stroud, C., Matney, C., & Bain, L. (2021, August 17). Targeting Glutamate Receptors for Treatment-Resistant Depression. Nih.gov; National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK575012/
Broad. (2017). Repurposing related drug annotations. Broadinstitute.org. https://repo-hub.broadinstitute.org/repurposing
Brown, E. N., Lydic, R., & Schiff, N. D. (2010). General Anesthesia, Sleep, and Coma. New England Journal of Medicine, 363(27), 2638–2650. https://doi.org/10.1056/nejmra0808281
Chen, J. (2022, March 9). How New Ketamine Drug Helps with Depression. Yale Medicine. https://www.yalemedicine.org/news/ketamine-depression
Clayton, T., & Ode, K. (2023). Mechanisms of action of general anaesthetic drugs. Anaesthesia & Intensive Care Medicine, 24(4), 235–237. https://doi.org/10.1016/j.mpaic.2022.12.031
Cleveland Clinic. (2022a, April 25). Gamma-Aminobutyric Acid (GABA). Cleveland Clinic. https://my.clevelandclinic.org/health/articles/22857-gamma-aminobutyric-acid-gaba
Cleveland Clinic. (2022b, April 25). Glutamate: What it is & function. Cleveland Clinic; Cleveland Clinic. https://my.clevelandclinic.org/health/articles/22839-glutamate
Das, J. (2020). Repurposing of Drugs–The Ketamine Story. Journal of Medicinal Chemistry, 63(22), 13514–13525. https://doi.org/10.1021/acs.jmedchem.0c01193
DrugBank. (2005, June 13). Ketamine. Go.drugbank.com. https://go.drugbank.com/drugs/DB01221
Dsquared. (2017, September). Delray Center. Delraycenter.com. https://www.delraycenter.com/ketamine-for-depression-treatment/
Green, S. M., & Johnson, N. E. (1990). Ketamine sedation for pediatric procedures: Part 2, review and implications. Annals of Emergency Medicine, 19(9), 1033–1046. https://doi.org/10.1016/s0196-0644(05)82569-7
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., Oquendo, M. A., & Mann, J. J. (2018). Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. American Journal of Psychiatry, 175(4), 327–335. https://doi.org/10.1176/appi.ajp.2017.17060647
Harrah, S. (2015, November 11). Medical Milestones: Discovery of Anesthesia & Timeline. Www.umhs-Sk.org; University of Medicine and Health Sciences. https://www.umhs-sk.org/blog/medical-milestones-discovery-anesthesia-timeline
Jewett, B. E., & Thapa, B. (2022, December 11). Physiology, NMDA Receptor. PubMed; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK519495/
Ji Woon Kim, Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023). Bridging rapid and sustained antidepressant effects of ketamine. Trends in Molecular Medicine, 29(5), 364–375. https://doi.org/10.1016/j.molmed.2023.02.003
Kulkarni, V. S., Alagarsamy, V., Solomon, V. R., Jose, P. A., & Murugesan, S. (2023). Drug Repurposing: An Effective Tool in Modern Drug Discovery. Russian Journal of Bioorganic Chemistry, 49(2), 157–166. https://doi.org/10.1134/s1068162023020139
Kurdi, M. S., Theerth, K. A., & Deva, R. S. (2014). Ketamine: Current applications in anesthesia, pain, and critical care. Anesthesia: Essays and Researches, 8(3), 283. https://doi.org/10.4103/0259-1162.143110
Li, L., & Vlisides, P. E. (2016). Ketamine: 50 Years of Modulating the Mind. Frontiers in Human Neuroscience, 10(612). https://doi.org/10.3389/fnhum.2016.00612
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020). Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Therapeutic Advances in Psychopharmacology, 10(10), 204512532091665. https://doi.org/10.1177/2045125320916657
Mayer, S. A., Claassen, J., Lokin, J., Mendelsohn, F., Dennis, L. J., & Fitzsimmons, B.-F. (2002). Refractory status epilepticus: frequency, risk factors, and impact on outcome. Archives of Neurology, 59(2), 205–210. https://doi.org/10.1001/archneur.59.2.205
Moore, T. J., Alami, A., Alexander, G. C., & Mattison, D. R. (2022). Safety and effectiveness of
NMDA
receptor antagonists for depression: A multidisciplinary review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 42(7), 567–579. https://doi.org/10.1002/phar.2707
Pain, N. (2014). National Pain Centers®. National Pain Centers®. https://www.nationalpain.com/routes-of-administration
Petrenko, A. B., Yamakura, T., Sakimura, K., & Baba, H. (2014). Defining the role of NMDA receptors in anesthesia: are we there yet? European Journal of Pharmacology, 723, 29–37. https://doi.org/10.1016/j.ejphar.2013.11.039
Research, C. for D. E. and. (2022). FDA alerts health care professionals of potential risks associated with compounded ketamine nasal spray. FDA. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-professionals-potential-risks-associated-compounded-ketamine-nasal-spray
Rosenbaum, S. B., & Palacios, J. L. (2024, January 30). Ketamine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK470357/
Son, Y. (2010). Molecular mechanisms of general anesthesia. Korean Journal of Anesthesiology, 59(1), 3. https://doi.org/10.4097/kjae.2010.59.1.3
Wink, L. K., Reisinger, D. L., Horn, P., Shaffer, R. C., O’Brien, K., Schmitt, L., Dominick, K. R., Pedapati, E. V., & Erickson, C. A. (2020). Brief Report: Intranasal Ketamine in Adolescents and Young Adults with Autism Spectrum Disorder—Initial Results of a Randomized, Controlled, Crossover, Pilot Study. Journal of Autism and Developmental Disorders, 51(4), 1392–1399. https://doi.org/10.1007/s10803-020-04542-z
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006). A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Archives of General Psychiatry, 63(8), 856. https://doi.org/10.1001/archpsyc.63.8.856
Zhou, C., & Tajima, N. (2023). Structural insights into NMDA receptor pharmacology. https://doi.org/10.1042/bst20230122
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016). Ketamine: NMDA Receptors and Beyond. The Journal of Neuroscience, 36(44), 11158–11164. https://doi.org/10.1523/jneurosci.1547-16.2016